Literature DB >> 12070832

Immune reconstitution after hematopoietic stem-cell transplantation and its influence on respiratory infections.

Melissa Matulis1, Kevin P High.   

Abstract

Hematopoietic stem-cell transplantation has evolved as the best therapeutic option for many patients with hematologic malignancy, and it is becoming more common as a treatment for metabolic and autoimmune disorders. The conditioning regimen given before transplantation virtually eliminates all pre-existing immunity, and the resulting immune deficits leave the host susceptible to a variety of respiratory infections, many of which carry significant morbidity and mortality. These deficits resolve over time with re-constitution of the immune system. However, the major arms of the immune response mature along different, but predictable, patterns depending on the underlying disorder, the source of stem cells used, and the presence of complications such as graft-versus-host disease. The immune deficit present at specific times posttransplant can assist in determining the most likely organisms to cause infection. This article outlines the recovery of immunity posttransplant, the most common pulmonary infectious complications, the noninfectious complications that mimic infection, and outlines appropriate preventive strategies in this group of markedly immunosuppressed patients. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12070832     DOI: 10.1053/srin.2002.33441

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  2 in total

1.  Twisting immune responses for allogeneic stem cell therapy.

Authors:  Shengwen Calvin Li; Jiang F Zhong
Journal:  World J Stem Cells       Date:  2009-12-31       Impact factor: 5.326

2.  Pulmonary complications after hematopoietic stem cell transplantation.

Authors:  Do Hyoung Lim; Jeeyun Lee; Hong Ghi Lee; Byeong-Bae Park; Kyong Ran Peck; Won Sup Oh; Sang Hoon Ji; Se-Hoon Lee; Joon Oh Park; Kihyun Kim; Won Seog Kim; Chul Won Jung; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Keunchil Park
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.